Colgate Palmolive Co SEC Filings

Grant Shane, COO, Americas at Colgate-Palmolive Company, reported equity awards on 09/11/2025. The filing shows a grant of 3,569 restricted stock units (RSUs) that vest in equal one-third installments on each of the first three anniversaries of the grant. The report also records a stock option award for 24,712 shares with an exercise price of $84.06; the option vests in equal annual installments over three years beginning on the first anniversary of the grant and expires on 09/11/2033. After these transactions, the reporting person beneficially owns 94,119 common shares and holds 24,712 underlying shares from the option award.

Jennifer Daniels, Chief Legal Officer and Secretary of Colgate-Palmolive Company (CL), reported equity awards granted on 09/11/2025. The filing shows a non-derivative acquisition of 4,592 common stock units (restricted stock units) at $0.00, leaving 77,980 shares directly beneficially owned after the transaction, plus 1,813 indirectly owned through the issuer's 401(k) plan trustee. The filing also reports a stock option award with an $84.06 exercise price for 31,796 options, exercisable in equal annual installments over three years beginning on the first anniversary of the 09/11/2025 grant and expiring 09/11/2033. The RSUs vest in three equal annual installments from the grant date. The form is signed by an attorney-in-fact on 09/12/2025.

Colgate-Palmolive (NYSE: CL) filed an 8-K dated 1 Aug 2025 reporting two material items.

• Item 2.02 – Earnings release: The Q2-25 earnings press release was furnished as Exhibit 99; the filing itself contains no revenue, EPS or margin data and is not deemed “filed” for Exchange Act liability purposes.
• Item 2.05 – Three-year Productivity Program: Approved 31 Jul 2025, the initiative is intended to support the company’s 2030 strategy by streamlining the organisational structure and optimising the global supply chain. Management expects cumulative pre-tax charges of $200-$300 million, classified in the Corporate segment, with substantially all costs recognised by 31 Dec 2028.

The company cautions that forward-looking statements about timing and amount of charges may differ materially from current projections. No cost-savings targets, head-count impacts or earnings guidance were disclosed.

Colgate-Palmolive (NYSE: CL) submitted a routine Form 3 – Initial Statement of Beneficial Ownership for newly reported insider John Hazlin, Chief Growth Officer.

The filing shows Hazlin directly owns 14,385 common shares and indirectly owns 5,382 shares through the company’s 401(k) plan, for a total of 19,767 shares of common stock. In addition, he holds five separate stock-option grants covering an aggregate 103,340 underlying shares with exercise prices ranging from $72.83 to $106.34 and expiration dates between 2028 and 2032. Vesting schedules are disclosed for each grant, generally becoming exercisable in one-third increments starting one year after the grant date.

No purchases, sales or other transactions occurred on the reported event date (06/16/2025); the form simply establishes Hazlin’s beneficial ownership under Section 16(a). The filing contains no financial results, strategic updates, or other material corporate events.